C R Jack

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 58:750-7. 2002
  2. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:294-301. 2009
  3. pmc Serial MRI and CSF biomarkers in normal aging, MCI, and AD
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 75:143-51. 2010
  4. pmc Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
  5. pmc Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 65:1227-31. 2005
  6. pmc Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:1850-7. 2008
  7. pmc Atrophy rates accelerate in amnestic mild cognitive impairment
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 70:1740-52. 2008
  8. pmc Two distinct subtypes of right temporal variant frontotemporal dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1443-50. 2009
  9. pmc DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:902-4. 2005
  10. pmc Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012

Collaborators

Detail Information

Publications56

  1. pmc Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 58:750-7. 2002
    ....
  2. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:294-301. 2009
    ....
  3. pmc Serial MRI and CSF biomarkers in normal aging, MCI, and AD
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 75:143-51. 2010
    ..Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials...
  4. pmc Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
    ..To investigate the combined ability of hippocampal volumes, 1H magnetic resonance spectroscopy (MRS) metabolites, and cerebrovascular disease to predict the risk of progression to dementia in mild cognitive impairment (MCI)...
  5. pmc Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 65:1227-31. 2005
    ....
  6. pmc Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:1850-7. 2008
    ....
  7. pmc Atrophy rates accelerate in amnestic mild cognitive impairment
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 70:1740-52. 2008
    ..We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN)...
  8. pmc Two distinct subtypes of right temporal variant frontotemporal dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1443-50. 2009
    ..We aimed to determine whether right temporal FTD is a homogeneous clinical, imaging, and pathologic/genetic entity...
  9. pmc DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:902-4. 2005
    ..002). Magnetic resonance diffusion-weighted imaging may help identify patients with aMCI who will progress to AD as well as or better than structural MRI measures of hippocampal atrophy...
  10. pmc Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012
    ..Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity...
  11. pmc APOE modifies the association between Aβ load and cognition in cognitively normal older adults
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:232-40. 2012
    ..To determine the relationship between β-amyloid (Aβ) load as measured by [(11)C]-Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults...
  12. pmc Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 77:393-8. 2011
    ..To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations...
  13. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:287-93. 2009
    ..To assess the correlations of both MRI and CSF biomarkers with clinical diagnosis and with cognitive performance in cognitively normal (CN) subjects and patients with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD)...
  14. pmc Caudate atrophy on MRI is a characteristic feature of FTLD-FUS
    K A Josephs
    Department of Neurology Behavioral Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Neurol 17:969-75. 2010
    ..We have observed severe caudate atrophy at autopsy in FTLD-FUS, and hence, we aimed to determine whether caudate atrophy on MRI is a feature that can distinguish FTLD-FUS from FTLD-TDP and FTLD-TAU...
  15. pmc MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology
    K Kantarci
    Departmentsof Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:771-8. 2010
    ..To determine the proton magnetic resonance spectroscopy ((1)H MRS) changes in carriers of microtubule-associated protein (MAPT) mutations in a case-control study...
  16. pmc Age-related changes in the default mode network are more advanced in Alzheimer disease
    D T Jones
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:1524-31. 2011
    ..To investigate age-related default mode network (DMN) connectivity in a large cognitively normal elderly cohort and in patients with Alzheimer disease (AD) compared with age-, gender-, and education-matched controls...
  17. pmc Diffusion tensor imaging and cognitive function in older adults with no dementia
    K Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:26-34. 2011
    ..To determine the patterns of diffusivity associated with cognitive domain functions in older adults without dementia...
  18. pmc Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1058-65. 2009
    ..To use a case-control study to assess and compare patterns of gray matter loss across groups of subjects with different mutations in the microtubule-associated protein tau (MAPT) gene...
  19. pmc Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 55:484-89. 2000
    ..69%, AD 3. 5%. CONCLUSION: Rates of hippocampal atrophy match both baseline cognitive status and the change in cognitive status over time in elderly persons who lie along the cognitive continuum from normal to MCI to AD...
  20. pmc Effects of age on the glucose metabolic changes in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    AJNR Am J Neuroradiol 31:1247-53. 2010
    ..Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI...
  21. pmc Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 52:1397-403. 1999
    ..CONCLUSION: In older patients with MCI, hippocampal atrophy determined by premorbid MRI-based volume measurements is predictive of subsequent conversion to AD...
  22. pmc Imaging correlates of pathology in corticobasal syndrome
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Neurology 75:1879-87. 2010
    ..The aim of this study was to determine whether patterns of atrophy on imaging could be useful to help predict underlying pathology in CBS...
  23. pmc Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI
    K Kantarci
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 74:1814-21. 2010
    ....
  24. pmc MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 70:512-20. 2008
    ..To compare the patterns of gray matter loss in subjects with amnestic mild cognitive impairment (aMCI) who progress to Alzheimer disease (AD) within a fixed clinical follow-up time vs those who remain stable...
  25. pmc Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:2212-20. 2010
    ..To determine whether TDP-43 type is associated with distinct patterns of brain atrophy on MRI in subjects with pathologically confirmed frontotemporal lobar degeneration (FTLD)...
  26. pmc The anatomic correlate of prosopagnosia in semantic dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 71:1628-33. 2008
    ..To determine the anatomic correlate of prosopagnosia in subjects with semantic dementia...
  27. pmc Mild cognitive impairment and Alzheimer disease: regional diffusivity of water
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:101-7. 2001
    ..Elevation in hippocampal ADC may reflect early ultrastructural changes in the progression of Alzheimer disease...
  28. pmc Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 77:866-74. 2011
    ....
  29. pmc Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN
    J L Whitwell
    Department of Radiology Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 72:813-20. 2009
    ..To compare patterns of gray matter loss in subjects with mutations in the progranulin (PGRN) gene to subjects with mutations in the microtubule-associated protein tau (MAPT) gene...
  30. pmc Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 49:786-94. 1997
    ..99 SD, and moderate AD (CDR 2) -2.22 SD. Age- and gender-adjusted, normalized MRI-based hippocampal volumetric measurements provide a sensitive marker of the MTL neuroanatomic degeneration in AD early in the disease process...
  31. pmc Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Eur J Neurol 20:1417-22. 2013
    ..The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS...
  32. pmc Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Neurol 20:629-37. 2013
    ..We aimed to compare, for the first time, atrophy patterns, as well as white matter tract degeneration, between these two syndromes...
  33. pmc Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 77:951-8. 2011
    ....
  34. pmc MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 71:743-9. 2008
    ..We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology...
  35. pmc 1H MR spectroscopy in common dementias
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    Neurology 63:1393-8. 2004
    ..To determine the 1H MR spectroscopic (MRS) findings and intergroup differences among common dementias: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD)...
  36. pmc Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
    C R Jack
    Department of Diagnostic Radiology and MR Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 62:591-600. 2004
    ....
  37. ncbi request reprint Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology
    G A Rippon
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurocase 11:204-11. 2005
    ..We suggest that PSP with or without coexisting AD and AGD be included in the differential diagnosis of patients presenting with FTD...
  38. ncbi request reprint Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans
    D Sencakova
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, Minn, USA
    Arch Neurol 58:1593-7. 2001
    ..The neuropsychological-hippocampal volume correlations indicate that hippocampal volume measurements do represent a measure of the structural substrate of functional impairment in AD...
  39. pmc Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia
    Y Jung
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Eur J Neurol 21:1040-3. 2014
    ..It is unclear whether the burden of underlying β-amyloid pathology is associated with language or general cognitive impairment in these subjects...
  40. pmc Functional inferences vary with the method of analysis in fMRI
    M M Machulda
    Department of Radiology, Magnetic Resonance Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neuroimage 14:1122-7. 2001
    ..Using data processing methods that are independent of the arbitrary selection of cutoff values for thresholding activation maps may reduce the likelihood of obtaining spurious results...
  41. pmc Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia
    D C Perry
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Eur J Neurol 19:911-7. 2012
    ..Obsessions and compulsive (OC) behaviors are a frequent feature of behavioral variant frontotemporal dementia (bvFTD), but their structural correlates have not been definitively established...
  42. pmc Progressive aphasia secondary to Alzheimer disease vs FTLD pathology
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:25-34. 2008
    ..The pathology causing progressive aphasia is typically a variant of frontotemporal lobar degeneration, especially with ubiquitin-positive inclusions (FTLD-U). Less commonly the underlying pathology is Alzheimer disease (AD)...
  43. ncbi request reprint Effects of a stereotactic headframe assembly on proton magnetic resonance spectroscopy
    N G Campeau
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Stereotact Funct Neurosurg 71:190-202. 1998
    ..5% from a spectrum obtained at the phantom center. The feasibility of performing single voxel MRS with a stereotactic headframe in place is demonstrated...
  44. pmc MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN, USA
    Neurology 60:253-60. 2003
    ..To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic trial for AD...
  45. pmc Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1843-9. 2009
    ..Because there is only limited longitudinal imaging data currently available, we measured the rate of change over 1 year of whole brain volume (WBV) and ventricular volume (VV) in patients with FTLD...
  46. ncbi request reprint The relationship between quantitative T2 relaxometry and memory in nonlesional temporal lobe epilepsy
    J D Wendel
    Department of Diagnostic Radiology, and Mayo Medical School, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Epilepsia 42:863-8. 2001
    ..Therefore, our findings support the use of quantitative T2 relaxometry as an independent predictor of verbal memory outcome in both left and right TLE patients who are candidates for temporal lobectomy...
  47. pmc Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 74:201-9. 2010
    ..Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally...
  48. pmc Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients
    M M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 61:500-6. 2003
    ..To determine whether an fMRI memory encoding task distinguishes among cognitively normal elderly individuals, patients with mild cognitive impairment (MCI), and patients with early Alzheimer's disease (AD)...
  49. doi request reprint Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Neurol 19:1440-6. 2012
    ..We refer to subjects with this presentation as Hybrids. The hybrid presentation is not rare, yet there are no studies that have assessed the neuroanatomical correlates of the hybrid syndrome to explain its occurrence...
  50. pmc FLAIR histogram segmentation for measurement of leukoaraiosis volume
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 14:668-76. 2001
    ..4% for leukoaraiosis volume and 0.3% for brain volume. We conclude that the FLAIR-histoseg method is an accurate and reproducible method for measuring leukoaraiosis and whole-brain volume in elderly subjects...
  51. pmc Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 86:438-41. 2009
    ..Ultimately, it is likely that the use of a combination of neuroimaging and chemical biomarkers will be involved in predicting the development of dementia and Alzheimer's disease (AD)...
  52. pmc Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain
    T M Wengenack
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neuroimage 54:113-22. 2011
    ....
  53. ncbi request reprint Total intracranial volume: normative values and lack of association with Alzheimer's disease
    S D Edland
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 59:272-4. 2002
    ..24) and 10.1 cm(3) larger for cases among men (n = 63 normal and 62 AD; p = 0.59). These differences are small and nonsignificant, suggesting that head size per se is not a critical determinant of AD...
  54. ncbi request reprint Cerebrospinal fluid-iophendylate contrast on gradient-echo MR images
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905
    Radiology 169:561-3. 1988
    ..Retained intraspinal iophendylate may mimic the appearance of intra-or extra-dural lesions, magnetic susceptibility artifact, and flow on gradient-echo MR images of the spine...
  55. ncbi request reprint Rapidly progressive hippocampal atrophy: evidence for a seizure-induced mechanism
    G A Worrell
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 58:1553-6. 2002
    ..5 months, the partial seizures did not become prolonged or secondarily generalized. Evidence from the patient indicates that partial seizure activity can cause rapid and progressive hippocampal atrophy...
  56. doi request reprint Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
    A S Fleisher
    Department of Neurosciences, University of California, San Diego, CA, USA
    Neurology 70:191-9. 2008
    ..To compare volumetric MRI of whole brain and medial temporal lobe structures to clinical measures for predicting progression from amnestic mild cognitive impairment (MCI) to Alzheimer disease (AD)...